Why IAG, Mayne Pharma, Mesoblast, & Temple & Webster shares are tumbling lower

Mayne Pharma Group Ltd (ASX:MYX) and Mesoblast limited (ASX:MSB) shares are two of four tumbling lower on Tuesday. Here’s why…
The post Why IAG, Mayne Pharma, Mesoblast, & Temple & Webster shares are tumbling lower appeared first on Motley Fool Australia. –

Chalkboard Graph Up Dow

In morning trade on Tuesday the S&P/ASX 200 Index (ASX: XJO) has given back its early gains and is dropping lower. At the time of writing the benchmark index is down 0.4% to 5,918.1 points.

Four shares that have fallen more than most today are listed below. Here’s why they are tumbling lower:

The Insurance Australia Group Ltd (ASX: IAG) share price has fallen 2% to $4.54. This morning the insurance giant revealed that it has settled the class action brought against it by Johnson Winter & Slattery. These proceedings relate to add-on insurance products sold through motor vehicle and motorcycle dealers. The settlement involves a gross payment of $138 million and is subject to approval by the Federal Court of Australia.

The Mayne Pharma Group Ltd (ASX: MYX) share price has crashed 17% lower to 31.5 cents after the release of an update. The pharmaceutical company advised that it has received a response from the US Food and Drug Administration (FDA) in relation to its abbreviated new drug application for a generic version of NUVARING. The FDA has raised questions about the application, which Mayne Pharma will address in a timely manner.

The Mesoblast limited (ASX: MSB) share price is down 2% to $3.48. This appears to have been driven by profit taking after a strong rebound in the Mesoblast share price on Monday. The biotech company’s shares have been very volatile since the FDA rejected its remestemcel-L application pending further trials.

The Temple & Webster Group Ltd (ASX: TPW) share price has fallen 4% to $11.74 despite there being no news out of the online furniture retail company. However, with the Temple & Webster share price up 360% year to date prior to today, I wouldn’t be surprised if some of this decline is related to profit taking from investors.

These 3 stocks could be the next big movers in 2020

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Temple & Webster Group Ltd. The Motley Fool Australia has recommended Temple & Webster Group Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why IAG, Mayne Pharma, Mesoblast, & Temple & Webster shares are tumbling lower appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!